The suspension of research funding, amounting to billions, has severely impacted cancer research at universities, leading to halted lab work and a pause in accepting new doctoral students.
This ongoing conflict between the Trump administration and higher education, combined with efforts to trim government spending, has significantly affected cancer research primarily at U.S. universities.
Experts express concern that the repercussions of these actions could hinder progress in cancer treatment for years, especially if cancer rates continue to rise.
“Many top scholars are contemplating leaving, fearing that we might lose a generation of exceptional researchers,” noted one expert.
“It could be two to three decades before we fully recover from the devaluation of research that occurred over just a few years,” they added.
Research initiatives are facing cuts at institutions targeted by the administration, especially due to perceptions of inaction on anti-Semitism and a reluctance to comply with presidential demands.
The president of Harvard has repeatedly pointed out that the billions in frozen funding will seriously hinder advancements in healthcare. Recently, Harvard even instituted a hiring freeze due to financial uncertainties brought on by the administration.
Moreover, cancer research grants are also suffering from funding cuts across other federal agencies, including the National Institutes of Health (NIH) and the Department of Health and Human Services (HHS). A recent analysis highlighted a staggering $1.5 billion cut from the NIH within a mere 40 days.
On top of dwindling grants, NIH has also seen a substantial workforce reduction.
“Agencies like Johns Hopkins and the University of California system are beginning to scale back staff,” shared a government relations official.
“There’s a trend of suspending new PhD or postdoc admissions, considering the uncertain funding outlook for this year and next. With the current federal budget proposing more than a 40% cut to the National Health Institute, I expect this trend to continue,” they noted.
A representative from HHS stated their commitment to cancer research and other significant health issues remains strong.
“These areas are a priority for both NIH and HHS. Ongoing investment demonstrates our resolve to tackle critical health challenges,” they emphasized.
The push for advancements in cancer treatment was notably sparked by former President Biden’s “Cancer Moonshot” initiative. Recently, he disclosed his own aggressive prostate cancer diagnosis, underscoring his intensified focus on the illness.
A report this month from minority staff on the Senate Health, Education, Labor and Pensions Committee disclosed that the Trump administration has cut $2.7 billion from NIH funding since January, warning this could lead to fewer breakthroughs and weaken public health responses.
HHS countered this report, claiming the “war on science” narrative was inaccurate.
“Leadership under @seckennedy prioritizes top-quality science to streamline programs and fulfill @Potus’ commitment to improve national health,” HHS stated.
However, with universities currently planning their upcoming budgets, the funding situation looks bleak. Institutions are left guessing about potential cuts, as the administration has indicated a firm stance against universities.
“The Trump administration has slowed the peer review process significantly, not funding as many projects as before, and also cutting numerous grants,” a representative explained.
“We anticipate challenging budget requests for 2026, with expected cuts from the National Institutes of Health proposed to be around $18 billion,” they added.
Elena Fuentes-Afflick, the chief science officer at the American Association of Medical Colleges, remarked that researchers are left asking for clarity as many termination notices issued by the government don’t align with agency priorities.
“Once grants end, researchers across the nation are often left without jobs if projects aren’t funded, and universities are trying to grasp the scope and duration of this issue,” she said.
Legal actions are emerging regarding NIL funding cuts, with 16 Democratic attorneys general challenging the lack of a proper review process and seeking restoration of funds.
Experts argue that previous investments in cancer research have led to discoveries that positively impacted various healthcare areas.
Federal funding for cancer research ramped up significantly after President Nixon declared a war on cancer in the 1970s.
“Since 1971, cancer research funding has surged, influencing treatments for other diseases, including prostate and lung cancers, as well as advancements for conditions like Crohn’s disease and rheumatoid arthritis,” one expert noted.
